Skip to main content
OpenTrials
Completed

NCT Number: NCT00234936

Quality of Life Study With Adalimumab in Rheumatoid Arthritis

The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history
  • Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria
  • Subjects with treatment failure criteria to Mtx or Mtx + another DMARD

Exclusion criteria

  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Previous treatment with approved biological agents (etanercept, infliximab, anakinra) in the last 2 months

Treatment and study plan

Adalimumab

Drug

methotrexate

Drug

Primary outcomes

  1. QOL

    Time frame: 12 months

Secondary outcomes

  1. Patient reported outcomes

  2. Clinical response indicators

  3. Safety parameters

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Important dates

Study start
2003
First posted
Oct 10, 2005
Registry last updated
Oct 3, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.